Explore how integrated collaboration among specialists is reshaping the psoriatic arthritis care pathway and optimizing ...

A multinational study shed light on which sites to scan for early signs of the disease, but scoring system was less sensitive ...

Ultrasound-based phenotyping distinguishes inflammatory and non-inflammatory forms of difficult-to-treat psoriatic arthritis, ...

Several racial and ethnic groups were significantly underrepresented in pivotal psoriatic arthritis trials performed between ...

We often imagine arthritis as a condition exclusive to people well into their golden years, yet data shows psoriatic ...

Dealing with the itchy, scaly patches that come with psoriasis is difficult enough. But having psoriasis puts you at risk of ...

With new systemic treatments now available for psoriatic disease, questions remain on the comparable efficacy and safety of these therapies.

Health experts reveal the impact of the inflammatory skin condition on joints, and highlight symptoms and management tips ...

In this video, Philip J. Mease, MD, discusses results from phase 3 clinical trials of deucravacitinib for psoriatic arthritis, presented at the EULAR 2025 Congress.

Self-care methods for psoriatic arthritis (PsA) include staying active with gentle exercises, getting enough sleep, and eating an anti-inflammatory diet.

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

As second-line therapy for PsA and axSpA, no clear treatment-retention benefit at 3 years was seen when swapping to a bDMARD with another MOA.